Related: Scientists can’t find any trace of HIV in man potentially “cured” via medication aloneThe new trial will test a gene therapy developed by biotech firm American Gene Technologies (AGT), based in Rockville, Maryland.Its HIV gene therapy is known as AGT103-T.
It involves removing some white blood cells from an HIV-positive patient, then inserting a gene that modifies the T-cells. This enables the cells to stop HIV replication.The HIV-resistant CD4 T-cells are then infused back into the patient, where they can duplicate and fight HIV.
A more-detailed, peer-reviewed paper on AGT103-T appeared in June in the journal, Molecular Therapy.Jeff Galvin, founder and chief executive officer of AGT, said in a statement, “I am confident AGT103-T.